×

Treasury takes aim at inversions

10:36 AM ET Tue, 5 April 2016

CNBC's David Faber reports on new regulations from Treasury which could impact the Pfizer-Allergan deal. Liav Abraham, Citi Pharmaceuticals analyst, provides perspective on what some call an "overreach" by the Treasury.